Journey Medical (DERM) Projected to Release Quarterly Earnings on Wednesday

Journey Medical (NASDAQ:DERM) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $20.32 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. The firm had revenue of $18.51 million during the quarter, compared to the consensus estimate of $18.36 million. Journey Medical had a negative net margin of 8.95% and a negative return on equity of 20.23%. On average, analysts expect Journey Medical to post ($0.13) EPS for the current fiscal year and $0.44 EPS for the next fiscal year.

Journey Medical Price Performance

DERM opened at $4.64 on Wednesday. The company has a fifty day moving average price of $6.39 and a 200-day moving average price of $6.64. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59. Journey Medical has a one year low of $4.31 and a one year high of $9.56.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DERM shares. Wall Street Zen downgraded Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research note on Thursday, October 15th. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Journey Medical in a research report on Monday, October 26th. Finally, B. Riley Financial restated a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Journey Medical in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Journey Medical currently has a consensus rating of “Hold” and a consensus target price of $14.00.

Journey Medical Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing prescription products for medical dermatology. The company targets conditions that affect the skin, hair and nails, with an emphasis on products that address significant patient needs and can be marketed through its specialty sales organization.

Its portfolio includes Qbrexza (glycopyrronium) cloth, a topical treatment for primary axillary hyperhidrosis, and Targadox (doxycycline hyclate) delayed-release capsules, which are used to treat moderate-to-severe inflammatory acne vulgaris.